Some of the described FGF21 analogues or activators are classified as anti-obesity and antidiabetic molecules that improve insulin sensitivity, ameliorate hepatosteatosis, and promote weight loss [14,15,16,17,18]. The gene discussed is FGF21; the disease is obesity disorder.